Single-trial assessment of gamma-frequency brain oscillations and their modulation using transcranial alternating current stimulation (tACS)
Abstract
INTRODUCTION
Gamma-band oscillations (30-200 Hz) support cognitive functions such as memory, perception, and decision-making, which are often impaired in neuropsychiatric disorders including schizophrenia, Alzheimer's disease, and Parkinson's disease. These disorders show distinct gamma abnormalities that are promising targets for transcranial alternating current stimulation (tACS). However, phase-specific adaptation of stimulation to ongoing gamma activity has long been considered unfeasible due to the low signal-to-noise ratio (SNR) of non-invasive recordings and stimulation-related artifacts. Recent advances in quantum sensing now offer improved SNR, enabling phase-locked modulation of gamma oscillations.
METHODS
We tested whether gamma-frequency brain oscillations can be assessed at the single-trial level and modulated by amplitude-modulated tACS (AM-tACS) in a phase-specific manner. Using 16 optically pumped magnetometers (OPMs), we recorded 40 Hz auditory steady-state responses (ASSRs) in 19 participants during AM-tACS applied over the temporal lobe at randomly assigned phase lags relative to the ASSR. Participants judged the loudness of auditory stimuli, while occipital stimulation served as a control condition. We hypothesized that AM-tACS would alter ASSR latency, a measure of cortical synchronization, and loudness perception only when targeting the temporal lobe.
RESULTS AND CONCLUSION
AM-tACS modulated both ASSR latency (p < 0.05) and loudness perception (p <…
How strong is the evidence?
Evidence Hub reads this as a randomized trial. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 19 participants or records.
Read the paper
Related studies
- Quantum dots: synthesis, bioapplications, and toxicity
- A Guide to In Silico Drug Design
- Quantum Computing for Healthcare: A Review
- Automated in Silico Design of Homogeneous Catalysts
- Identification of Novel 3-Hydroxy-pyran-4-One Derivatives as Potent HIV-1 Integrase Inhibitors Using in silico Structure-Based Combinatorial Library Design Approach
- In silico structural elucidation of RNA-dependent RNA polymerase towards the identification of potential Crimean-Congo Hemorrhagic Fever Virus inhibitors
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.